References
- Heffler S, Levit K, Smith S et al. Health spending growth up in 1999; faster growth expected in the future. Health Affairs 2001; 20: 193–203.
- Holloway RG. Cost-effectiveness analysis: what is it and how will it influence neurology? Ann Neurol 1996; 39: 818–823.
- Neumann RJ, Sandberg E, Bell C et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs 2000; 19: 92–109.
- Drummond MF, Richardson WS, O’Brien BJ et al. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? JAMA 1997; 277: 1552–1557.
- O’Brien BJ, Heyland D, Richardson WS et al. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? JAMA 1997; 277: 1802–1806.
- Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Affairs 2001; 20: 104–114.
- Ubel PA. Pricing Life. Why it’s time for health care rationing. Cambridge MA: MIT Press, 2000.
- Ubel PA, Baron J, Nash B, Asch DA. Are preferences for equity over efficiency in health care allocation `All or Nothing?’ Med Care 2000; 38: 366–373.
- Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraint: Is it equitable? N Engl J Med 1996; 334: 1174–1177.
- Holloway RG, Ringel SP, Bernat J et al. US neurologists: Atti- tudes on resource allocation. Neurology 2000; 55: 1492–1497.